German registry data suggest apremilast monotherapy improves psoriasis severity and quality of life over 12 months, with ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, ...

Metabolic bariatric surgery (MBS) is associated with improved outcomes in patients with psoriasis, according to a review ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Living with a chronic skin condition such as psoriasis can significantly affect quality of life, particularly when ...

Learn what collagen is, why it may or may not have benefits for psoriasis, according to experts, and what the research has found so far.

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. The stock rose 8.9% to $9.05 in after-hours trading ...

Shares of Takeda Pharmaceuticals rose after the Japanese pharmaceutical major announced positive results from clinical trials of its new treatment for plaque psoriasis. The stock climbed 4.3% in early ...